New Treatments for Cutaneous Metastatic Melanoma: MAPK Pathway-Targeted and Immune Based Therapies

ISSN: 1875-5992 (Online)
ISSN: 1871-5206 (Print)


Volume 16, 12 Issues, 2016


Download PDF Flyer




Anti-Cancer Agents in Medicinal Chemistry

Formerly: Current Medicinal Chemistry - Anti-Cancer Agents

This journal supports open access

Aims & ScopeAbstracted/Indexed in

Ranking and Category:
  • 27th of 59 in Chemistry, Medicinal

Submit Abstracts Online Submit Manuscripts Online

Editor-in-Chief:
Michelle Prudhomme
Universite Blaise Pascal - C.N.R.S
Aubiere Cedex
France


View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 2.722
5 - Year: 2.849

New Treatments for Cutaneous Metastatic Melanoma: MAPK Pathway-Targeted and Immune Based Therapies



Anti-Cancer Agents in Medicinal Chemistry, 15(4): 461-467.

Author(s): F. Ranchon, A. Boespflug, C. Rioufol, V. Schwiertz, L. Thomas and S Dalle.

Affiliation: Dermatology Unit, Hospices Civils de Lyon, CH Lyon Sud, 165 chemin du Grand Revoyet, 69495 Pierre Benite Cedex, France.

Abstract

Increasing knowledge on cellular biology has permitted rapid changes in the treatment of metastatic melanoma. Until 2011, dacarbazine was the gold standard treatment at our disposal. In 2011 the treatment landscape changed dramatically with the approval by the FDA of ipilimumab and vemurafenib. These drugs use two new therapeutic approaches: immunomodulation and the targeting of mutated cellular pathways in tumor cells.

These two drugs, used as single agents have shown important increases in overall survival, unseen before in patients with advanced melanoma, but are limited by their toxicities and the appearance of acquired resistances.

In this article, we review new therapeutic options in pathway-targeted –with the arrival of MEK inhibitors - and immune based melanoma therapies –with the arrival of anti-PD1 and anti-PDL1- as well as new therapeutic strategies developed to overcome acquired resistance and diminish drug toxicities.





Keywords:

anti-PD1, anti PDL1, BRAF inhibitors, combination therapies, dabrafenib, immune based therapies, ipilimumab, MEK inhibitors, melanoma, vemurafenib.



Purchase Online Order Reprints Order Eprints Rights and Permissions




Article Details

Volume: 15
Issue Number: 4
First Page: 461
Last Page: 467
Page Count: 7
DOI: 10.2174/1871520615666150101125028
Price: $58
Advertisement

Related Journals




Webmaster Contact: urooj@benthamscience.org Copyright © 2016 Bentham Science